Antiangiogenic Therapy and p53
- 26 July 2002
- journal article
- editorial
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 297 (5581) , 471
- https://doi.org/10.1126/science.297.5581.471a
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Effect of p53 Status on Tumor Response to Antiangiogenic TherapyScience, 2002
- Angiogenesis-dependent diseasesSeminars in Oncology, 2001
- Downmodulation of bFGF-binding protein expression following restoration of p53 functionCancer Gene Therapy, 2001
- Heterogeneous Vascular Dependence of Tumor Cell PopulationsThe American Journal of Pathology, 2001
- p53 Checkpoint-Defective Cells Are Sensitive to X Rays, but Not HypoxiaExperimental Cell Research, 2000
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJournal of Clinical Investigation, 2000
- Disruption of p53 in human cancer cells alters the responses to therapeutic agentsJournal of Clinical Investigation, 1999
- Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in MiceScience, 1999
- Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumoursNature, 1996
- Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agentsBioEssays, 1991